Reviewed by Dr. Elena Vance, DOLast reviewed 4 sources cited
Quick Summary
Rybelsus (semaglutide) and Victoza (liraglutide) are both glp-1 receptor agonists. In clinical trials, Rybelsus showed greater weight loss (4.4% vs 3.2%).
See the comparison table below for detailed side-by-side data.
Rybelsus vs Victoza: Full Comparison
| Feature | Rybelsus(semaglutide) | Victoza(liraglutide) |
|---|---|---|
| Active Ingredient | semaglutide | liraglutide |
| Drug Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA Approved | 2019-09-20 | 2010-01-25 |
| Approved Indications |
|
|
| Route | oral | subcutaneous injection |
| Frequency | Once daily | Once daily |
| Starting Dose | 3 mg daily | 0.6 mg daily |
| Maintenance Dose | 7 mg or 14 mg daily | 1.2 mg or 1.8 mg daily |
| Max Dose | 14 mg daily | 1.8 mg daily |
| Weight Loss (%) | 4.4% | 3.2% |
| A1C Reduction | 1.4% | 1.1% |
| Key Trial | PIONEER 1 (26 weeks) | LEADER (188 weeks) |
| List Price | $935-$1,029/month | $950-$1,100/month |
| With Insurance | $25-$150/month (varies by plan) | $25-$150/month (varies by plan) |
| Savings Card | $10/month (Novo Nordisk savings card, commercially insured) | $25/month (Novo Nordisk savings card, commercially insured) |
Side Effects: Rybelsus vs Victoza
| Side Effect | Rybelsus | Victoza |
|---|---|---|
| Nausea | 11-20% | 28% |
| Abdominal pain | 5-11% | Not reported |
| Diarrhea | 5-10% | 17% |
| Decreased appetite | 3-9% | 9% |
| Vomiting | 4-8% | 11% |
| Constipation | 3-5% | 6% |
| Pancreatitis (rare) | <0.5% | <1% |
| Headache | Not reported | 9% |
| Dyspepsia | Not reported | 7% |
Severity scale: 1 (mild) to 5 (serious). Based on FDA prescribing information and clinical trial data.
Related Comparisons
Frequently Asked Questions
Sources & References
This content is for informational purposes only and is not medical advice. Always consult your healthcare provider before making medication decisions. See our full medical disclaimer.